On Thursday, Eli Lilly and Company's (NYSE:LLY) price target was raised to $957 from the previous $925 by Jefferies, while the firm maintained a Buy rating on the pharmaceutical company's shares.
Eli Lilly announced impressive Q1 2024 financial results, with revenue surging by 26% YoY and exceeding expectations for earnings per share. The company raised its full-year 2024 revenue guidance ...
Eli Lilly and Company announced that Anat Ashkenazi has decided to step down as chief financial officer. 1 She will continue to serve in the role through July 2024, at which point she will pursue a ...
Glencar has taken over the construction of a life sciences building near Cambridge from collapsed contractor Readie. Readie ...
, opens new tab named Anat Ashkenazi as its chief financial officer on Wednesday, turning to a top executive from drugmaker Eli Lilly (LLY.N) , opens new tab to help steer the Google parent in the ...
Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Alphabet Inc. named Eli Lilly & Co. executive Anat Ashkenazi as its new chief financial officer, replacing Ruth Porat who announced last year she planned to step down. Ashkenazi, 51, has served as ...
Last year in March, Eli Lilly released the results of the TRAILBLAZER-ALZ 2 Phase 3 study of donanemab for Alzheimer's disease. In March last year, Eli Lilly released the results of the ...
On Thursday, Eli Lilly and Company's (NYSE:LLY) price target was raised to $957 from the previous $925 by Jefferies, while the firm maintained a Buy rating on the pharmaceutical company's shares. The ...